Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
November 04 2022 - 8:30AM
Business Wire
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression and other central nervous system
(CNS) disorders, today announced it will host a conference call and
webcast on Thursday, November 10, 2022, at 2:00 p.m. Pacific Time
(5:00 p.m. Eastern Time) to report financial results for its fiscal
year 2023 second quarter ended September 30, 2022.
Event: Vistagen Fiscal Year 2023 Second Quarter Results
Conference Call Date: Thursday, November 10, 2022
Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US
Dial-in (Toll Free): 1-888-599-8686 TOLL/International
Dial-in: 1-929-477-0402 Conference ID: 5975082
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1579342&tp_key=aa33644740
An audio webcast of the conference call will also be available
via the link provided above. Participants should access this
webcast site 10 minutes before the start of the call. In addition,
a telephone playback of the call will be available after
approximately 5:00 p.m. Pacific Time on Thursday, November 10,
2022. To listen to the replay, call toll free 1-844-512-2921 within
the United States or 1-412-317-6671 when calling internationally
(toll). Please use the replay PIN number 5975082.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage CNS-focused
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. The Company is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available.
Vistagen’s clinical-stage candidates are targeting multiple forms
of anxiety and depression. Candidates include PH94B and PH10, which
belong to a new class of drugs known as pherines, which are
investigational neuroactive steroids designed with a novel
rapid-onset mechanism of action that activates chemosensory neurons
in the nasal passages and can impact the olfactory-amygdala neural
circuits without systemic uptake or direct activity on CNS neurons
in the brain. Vistagen is passionate about transforming mental
health care and redefining what is possible in the treatment of
anxiety and depression – one mind at a time. Connect at
www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221104005192/en/
Investors Mark Flather Vice President, Investor Relations
Phone: (650) 577-3617 Email: mflather@vistagen.com
Media Nate Hitchings SKDK Email:
nhitchings@skdknick.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024